New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 5

Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

, , ,

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
EP. 3: Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
EP. 4: Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
Now Viewing
EP. 5: Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
EP. 6: Panel Discuses Use of CD19 Bispecifics in Sequencing
EP. 7: Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
EP. 8: Current Approach to Bridging Therapy in R/R DLBCL
EP. 9: Risk of Secondary Malignancies in Heavily Pre-Treated Population
EP. 10: Management of CRS and ICANS with CAR T-cell Therapy
EP. 11: Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
EP. 12: Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
EP. 13: Bispecific therapy – treatment setting and management of short-term adverse events
EP. 14: Bispecific therapy – management of long-term adverse events in the community setting
EP. 15: Practice Patterns and Real Use of Epcoritamab and Glofitamab
EP. 16: Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

  • For a patient who does not receive second-line cellular therapy whether based on logistical or clinical reasons, what would be your choice of approved therapies?
    • When choosing a second-line therapy for a patient not eligible for transplant or CAR T-cell therapy, what most impacts your decision? Drug approval? NCCN guidelines? Based on what first-line treatment was received?
  • Please review the final 5-year data of the L-MIND study evaluating tafasitamab + lenalidomide.